by The global Infectious Disease Therapeutics Market is estimated to be valued at US$ 170.67 Bn or Mn in 2023 and is expected to exhibit a CAGR of 3.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Infectious diseases are caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi. These diseases cause millions of deaths worldwide every year. Infectious disease therapeutics are drugs used for treating infectious diseases. The global infectious disease therapeutics market has shown great potential, due to the increasing prevalence of various infectious diseases and rising investment in research and development of novel drugs by key players. Technological advancements have enabled development of targeted therapies against specific pathogens. Moreover, ongoing clinical trials for drugs to treat multidrug-resistant infections will further support market growth.
Market key trends:
One of the key trends in infectious disease therapeutics market is growing research on advanced therapies such as gene and cell therapies. These therapies aim to repair or replace dysfunctional cells and offer cure for presently incurable infectious diseases such as HIV/AIDS. Moreover, with rise in antimicrobial resistance, there is increased focus on development of novel drug classes such as antivirals, monoclonal antibodies and vaccines. Companies are investing heavily in R&D of first-in-class drugs to treat serious threat posed by resistant pathogens. Furthermore, adoption of personalized medicine and companion diagnostics provide optimized treatment outcomes.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as the infectious disease therapeutics market requires huge R&D investment and regulatory approvals.
Bargaining power of buyers: The bargaining power of buyers is moderate due to the presence of several pharmaceutical manufacturers. However, buyers have less bargaining power due to life-saving nature of products in the market.
Bargaining power of suppliers: The bargaining power of suppliers is low as there are multiple raw material suppliers. Also, switching costs from one supplier to another is low.
Threat of new substitutes: The threat of new substitutes is low in the market as a new disease requires extensive research and no vaccine/drug offers complete substitute.
Competitive rivalry: The competitive rivalry is high due to the presence of several global and local players offering generic and patented drugs.
Key Takeaways
The Global Infectious Disease Therapeutics Market Size is expected to witness high growth, exhibiting CAGR of 3.7% over the forecast period, due to increasing prevalence of infectious diseases.
Regional analysis
North America is expected to dominate the infectious disease therapeutics market during the forecast period. The rising incidence of infectious diseases, well-established healthcare system, and presence of major market players in the region is fueling the market growth.
Key players
Key players operating in the infectious disease therapeutics market are Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K), Merck & Co. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca (U.K), Mylan N.V. (U.S.), Novartis AG (Switzerland), Sanofi (France).
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
